More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.
C4 Therapeutics Inc.’s degrader-antibody conjugate (DAC) strategy gathered more steam with a new collaboration between the firm and Roche AG that brings $20 million up front with the potential for more than $1 billion in discovery, regulatory and commercial milestone payments.
In a decision that maintains the regulatory status quo, the U.S. FDA denied a petition from Harrison.ai to partially exempt certain diagnostic/detection AI devices from premarket review so long as the manufacturer has 510(k) clearance for a device in a similar category and a robust postmarket plan.
Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027.
Affirma Biotech SL has disclosed new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors potentially useful for the treatment of cancer, bacterial, fungal and viral infections.
Ewha Womans University and Gachon University have discovered new pyrazinocarbazole derivatives acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of colorectal cancer.
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune responses. In cancer, however, this inhibitory role can impair the immune system’s capacity to detect and eradicate tumor cells. Researchers from Genentech Inc. presented the design and optimization of a series of CBL-B-targeting molecular glues.
The N6-methyladenosine (m6A) RNA modification has a role in cancer progression, including renal cell carcinomas (RCCs). Recent work showed that KIAA1429, which serves as a scaffold for the m6A methyltransferase holocomplex, is significantly upregulated in hepatocellular carcinoma tissues and presents oncogenic roles in breast and gastric cancers. However, the potential role of KIAA1429 in clear cell RCC and its underlying regulatory mechanism remain largely unknown.
Understanding epi-transcriptome changes in diffuse midline gliomas H3 K27-altered (DMGs) could provide novel therapeutic options. RNA N6-methyladenosine (m6A) is a key epi-transcriptomic modification regulating RNA processes. A recently published study from the University of Sydney and collaborating institutions aimed to explore the m6A landscape in DMG.
RSS
